A convergent trend is emerging around relapsed/refractory small cell lung cancer (SCLC): the disease evolves under therapeutic pressure into a biologically distinct, YAP1-positive drug-tolerant persister (DTP) state. This DTP population, identified through paired biopsies, circulating tumor DNA, and circulating tumor cells, exhibits large cell neuroendocrine carcinoma-like features and a remodeled surface antigen profile—loss of canonical targets DLL3 and SEZ6, with concomitant enrichment of B7-H3 and TROP2. This antigen-switching phenomenon directly explains clinical treatment resistance and chemoresistance, and reframes relapsed SCLC not as a static target but as a moving one, necessitating adaptive or combinatorial targeting strategies. This mechanistic insight is now translating into a next generation of antibody-drug conjugates (ADCs) and cellular therapies designed to intercept these newly exposed vulnerabilities.
ABBV-706 exemplifies this trajectory as a first-in-class SEZ6-targeted ADC, achieving a 52% objective response rate in a 124-patient relapsed/refractory SCLC cohort, with a recommended Phase 2 dose (1.8 mg/kg Q3W) selected over a higher 2.5 mg/kg dose to optimize the efficacy-tolerability balance (61% Grade ≥3 TRAEs, 38% fatigue), yielding a 12.4-month median overall survival. In parallel, the B7-H3 axis—identified as enriched on YAP1+ DTP cells—is being exploited via QH104, an off-the-shelf, intrathecally delivered allogeneic B7-H3 CAR γδ T-cell therapy. Though tested in a small proof-of-concept Phase 1 trial (n=3, including SCLC-, lung adenocarcinoma-, and TNBC-derived leptomeningeal metastases), QH104 demonstrated tolerability, CSF cytology conversion, and IFN-γ-associated immune remodeling, establishing feasibility for treating CNS-compartment disease with engineered cell therapies. Together these programs signal a shift from single-antigen ADC strategies (DLL3-era) toward a broader antigen portfolio (SEZ6, B7-H3, TROP2) and modality diversification into CAR-based platforms capable of reaching sanctuary sites like the leptomeninges.
Complementing this antigen-directed trend, molecular stratification is advancing via MTAP deletion profiling across thoracic malignancies (lung adenocarcinoma and squamous cell carcinoma, 8-20% prevalence), which co-occurs with CDKN2A loss and with actionable drivers (ALK, ERBB2) and correlates with lower tumor mutational burden—nominating MTAP synthetic lethal therapy as a genomically defined complement to antigen-based approaches. Separately, PD-1 blockade combinations (tislelizumab with intratumoral sodium bicarbonate in hepatocellular carcinoma, or with liposomal mitoxantrone in relapsed/refractory extranodal NK/T-cell lymphoma) illustrate the broader industry pattern of pairing checkpoint inhibitors with novel partners as salvage regimens in refractory, poor-prognosis populations, reinforcing manageable toxicity and antitumor activity as key benchmarks across tumor types. Collectively, these threads point to a macro trend of resistance-informed, multi-modal precision oncology—leveraging real-time tumor evolution (antigen switching, genomic co-deletions) to guide ADC design, CAR T engineering, and immunotherapy combinations in hard-to-treat relapsed cancers.